Extended Data Fig. 5: Characterizing macrophages and the response to treatment. | Nature Biomedical Engineering

Extended Data Fig. 5: Characterizing macrophages and the response to treatment.

From: Macrophage-augmented organoids recapitulate the complex pathophysiology of viral diseases and enable development of multitarget therapeutics

Extended Data Fig. 5

a, Gating strategies for flow cytometry analysis of macrophage markers. b, Expression of M1 markers (HLA DR, CD80) and M2 markers (DC-SIGN, CD163) in undifferentiated THP-1 monocytes, and M0, M1, M2 macrophages derived from THP-1 monocytes. c, Representative images of macrophage subtypes. d, The effects of the NF-κB inhibitor (BAY11-7085, Bay11), caspae-1 inhibitor (VX-765;VX) and NLRP3 inhibitor (MCC950; MCC) on IL-6, TNF-α, CCL2 and IL-10 RNA levels quantified by qRT-PCR in HEV infected MaugOs (n = 4), complementary to Fig. 6c. e, IL-10 cytokine production quantified by ELISA (n = 4),), complementary to Fig. 6i. f and g, Quantification of IL-1β and TNF-α gene expression in HEV infected MaugOs treated with ribavirin (RBV), dexamethasone (DEX) or the combination (n = 4), complementary to Figs. 6k and 6l. h, Quantification of IL-10 RNA and protein levels (n = 4). i, IL-10 cytokine production in HEV infected MaugOs (M1) treated with ribavirin, dexamethasone (DEX) or the combination (n = 4), complementary to Fig. 6o. (d-i) Data are mean ± SD. *p < 0.05; **p < 0.01; Two-tailed Mann-Whitney U test. Exact p values are labelled, ‘n’ refers biological replicates.

Back to article page